Podcast Episodes

Quick Bite: What's the $50,000 Rule in NZ Foreign Investing?

In this quick bite, we dive deep into the world of offshore investing for New Zealanders. Mark Lash from Deloitte Private breaks down the complexities of the Foreign Investment Fund (FIF) regime, exp…

Published on 1 year, 5 months ago

Tax for investors 101

Is tax something you dread or would rather avoid?  We’ve got you covered. 

We ask common questions and chat about what you need to know about your tax as a retail investor.  

Mark Lash, a partner wit…

Published on 1 year, 5 months ago

Quick Bite: The Japanese stock market hit all time high in 2024

In this quick bite: Chris Di Leva from Harbour Asset Management discusses the surprising performance of the Japanese stock market with host Dan Brunskill. Did you know Japan's market hit an all-time …

Published on 1 year, 5 months ago

The US v NZ investing conundrum

Why invest locally when the action appears to be in the US? 

The meteoric rise of US chipmaker NVIDIA and the dominance of high earning tech stocks makes it hard for the likes of the NZX and ASX to c…

Published on 1 year, 5 months ago

Quick Bite: How crucial are ports to New Zealand's economy?

In this quick bite: Todd Dawson, CEO of Napier Port, discusses the vital role of ports in New Zealand's economy. Did you know 90% of the country's exports and imports travel by sea? Plus what are the…

Published on 1 year, 6 months ago

Why invest in a port? Napier Port CEO Todd Dawson

Ports are critical to our island nation given more than 90% of our exports and imports travel by sea. 

Our conversation with Napier Port CEO Todd Dawson explores how a traditional business has embrac…

Published on 1 year, 6 months ago

Quick Bite: Can AI Speed Up Drug Discovery?

In this quick bite we talk to Dr Deborah Lambie, global equity analyst at Milford Asset Management, about how cutting-edge technologies like AI-driven molecular design, accelerated simulations, and t…

Published on 1 year, 6 months ago

Weight loss drug boom—opportunities & risks

US big pharma, including Ozempic maker Novo Nordisk, continue to make huge gains from the new generation of obesity drugs. But how do investors weigh up the potential of this industry?    

We talk to…

Published on 1 year, 6 months ago

Quick Bite: What makes a 'great New Zealand company'?

In this quick bite: Infratil CEO Jason Boyes reflects on why it’s important for the infrastructure company to not only grow globally, but still appeal to the hearts and minds of NZers.

For more or to…

Published on 1 year, 6 months ago

How has Infratil sustained double digit growth?

What’s next for the market darling infrastructure investment company infratil? Can it maintain double digit growth? 

We talk to Infratil CEO Jason Boyes as the company reflects on 30 years and its $1…

Published on 1 year, 6 months ago